Skip to main content

Summit Therapeutics PLC (SMMT)

NASDAQ: SMMT · IEX Real-Time Price · USD
4.98 -0.08 (-1.58%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap478.14M
Revenue (ttm)615,000
Net Income (ttm)-73.05M
Shares Out90.65M
EPS (ttm)-0.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume121,244
Open5.09
Previous Close5.06
Day's Range4.90 - 5.13
52-Week Range3.22 - 12.30
Beta0.88
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva pl...

IndustryBiotechnology
Founded2003
Employees79
Stock ExchangeNASDAQ
Ticker SymbolSMMT
Full Company Profile

Financial Performance

Financial numbers in millions GBPFinancial Statements

News

Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. M...

2 weeks ago - GlobeNewsWire

(SMMT) Alert: Did You Lose Money on Your Summit Therapeutics Investment? Contact Johnson Fistel Regarding Investigation

SAN DIEGO, Oct. 2, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Summit Therapeutics Inc. ("Summit" or the ...

2 weeks ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc. - SMMT

New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investo...

3 weeks ago - Newsfile Corp

Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investig...

Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is the jo...

3 weeks ago - GlobeNewsWire

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...

3 weeks ago - PRNewsWire

FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials

Summit Therapeutics Inc (NASDAQ: SMMT) announced that the FDA disagrees with its proposed change to the primary endpoint in Phase 3 Ri-CoDIFy studies. In a regulatory filing, the Company said that the f...

1 month ago - Benzinga

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended Ju...

Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its o...

2 months ago - GlobeNewsWire

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbio...

Data Additionally include Potential Benefit for the Control of Antimicrobial Resistance and a Novel Mechanism of Action Data Additionally include Potential Benefit for the Control of Antimicrobial Resis...

3 months ago - GlobeNewsWire

Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Ra...

Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research updates at...

3 months ago - GlobeNewsWire

Summit Therapeutics set to join Russell 3000® Index

Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconsti...

4 months ago - GlobeNewsWire

Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?

Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...

5 months ago - Zacks Investment Research

Summit Therapeutics Stock Surges Higher But Slams Into A Wall Of Resistance

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) stock had a big move higher Monday. After reporting earnings and giving a clinical trial update, the stock gained $1.44 a share, a move of almost 27%.

5 months ago - Benzinga

Summit Therapeutics Unveils Preclinical Candidate For Multidrug-Resistant Infections

Summit Therapeutics Inc (NASDAQ: SMMT) has selected a new preclinical candidate, SMT026738 (SMT-738), for development against multidrug-resistant infections, specifically carbapenem-resistant Enterobact...

5 months ago - Benzinga

These 2 Nasdaq Stock Winners Could Change the World

Find out why investors are more excited than ever about these two businesses.

Other symbols:APPH
5 months ago - The Motley Fool

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021

Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.

5 months ago - GlobeNewsWire

Summit Therapeutics Announces Closing of $75 Million Rights Offering

Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.

5 months ago - GlobeNewsWire

Summit Therapeutics Publishes Scientific Updates to Corporate Website

Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational ...

5 months ago - GlobeNewsWire

Summit Therapeutics' Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscr...

Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time ...

5 months ago - GlobeNewsWire

Summit Therapeutics Announces Commencement of Rights Offering

Summit Therapeutics Inc. (‘Summit' or the ‘Company')

6 months ago - GlobeNewsWire

Summit Therapeutics Announces Rights Offering

Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Com...

6 months ago - GlobeNewsWire

Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer

Summit Therapeutics Inc. (‘Summit,' the ‘Company,' or the ‘Group')

10 months ago - GlobeNewsWire

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended Se...

Summit Therapeutics Inc. (‘Summit', the ‘Company' or the ‘Group')

11 months ago - GlobeNewsWire

Summit Announces Closing of Private Placement of $50 Million

Summit Therapeutics Inc. (“Summit” or the “Company”)

11 months ago - GlobeNewsWire

Summit Announces Agreement For a Fundraising of approximately $50 Million

Summit Therapeutics Inc.

1 year ago - GlobeNewsWire